Director DiSanto bought 50,000 XELB shares at $0.35; stock down -85.8% from 52-week high of $6.85 amid -53.5% revenue decline and -$7.9M net loss.
Director Mark DiSanto acquired 50,000 shares at $0.35 on 2025-12-05, increasing his holdings by 17.4% to 337,018 shares. This marks his third open-market purchase at XELB; his prior two buys at this ticker generated 90-day returns of +14.6% and +985.1%, both well-timed based on subsequent price movement. However, the current transaction occurs in a sharply deteriorated operating context: the company posted revenue of $1.1M against a net loss of $-7.9M in the latest quarter, with full-year annual revenue down -53.5% and the stock trading -85.8% below its 52-week high of $6.85. The $0.97 current price reflects a -17.1% decline over 30 days and -34.0% over 90 days—a material drawdown from the $0.35 purchase price. While DiSanto's cross-ticker track record shows strong prior execution (100% 90-day win rate, averaging +499.8% return), his same-ticker history at XELB demonstrates timing skill, yet the fundamental deterioration (unprofitable, sharply declining revenue) and ongoing share-price weakness warrant caution about whether historical timing patterns remain predictive in this altered environment.
Director DiSanto Mark bought 91.8K shares of XELB at $1.10, doubling position to 163.6K shares amid -86.1% decline from 52-week high.
Director DiSanto Mark purchased 91,800 shares at $1.10 on 2025-08-04, increasing his holdings from 71,783 to 163,583 shares (a +127.9% increase in share count). The transaction occurs at a price significantly below the 52-week high of $8.15, with the stock currently trading at $1.13, down -26.1% over 30 days and -52.3% over 90 days. Notably, his only prior purchase at this ticker on 2024-03-15 produced a 90-day return of +985.1%, suggesting past timing acuity. However, this must be weighed against fundamental deterioration: the company reported a net loss of $-2.8M last quarter on revenue of $1.3M, with annual revenue declining -53.5% year-over-year and an unprofitable full fiscal year. The purchase magnitude and price level relative to recent history warrant attention to whether this represents conviction or reflects valuation-driven opportunism in a distressed equity.
